No Data
No Data
Myriad Genetics Reports Strong Growth Amid Challenges
Express News | Myriad Genetics Shares Are Trading Lower Following a Q4 Revenue Miss and FY25 Revenue Guidance Below Estimates. The Stock May Also Be Trading on Weakness After It Announced It Will Face Cost Restructuring Following UnitedHealthcare's Decision to End...
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
Why Myriad Genetics (MYGN) Shares Are Plunging Today
Myriad Genetics Is Maintained at Neutral by UBS
Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer